Pfizer Confirms: Leading JAK Inhibitor Often Comes With Weight Gain

(MedPage Today) — Patients taking tofacitinib (Xeljanz) in the drug’s late-stage and post-marketing studies were more likely than those on placebo to gain weight and body mass index (BMI) points, pooled data from more than 5,000 rheumatoid arthritis…